JPMorgan raised the firm’s price target on Inspire Medical (INSP) to $118 from $82 and keeps a Neutral rating on the shares. The firm updated the company’s model to reflect its increased reimbursement rates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Oppenheimer upgrades Inspire Medical to Outperform on CMS blunder
- Inspire Medical upgraded to Outperform from Perform at Oppenheimer
- Inspire Medical price target raised to $165 from $135 at Piper Sandler
- Inspire Medical price target raised to $180 from $125 at Baird
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls